# Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

> **NCT03525119** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 900 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** TDV
- **BIOLOGICAL:** HAV Vaccine
- **BIOLOGICAL:** TDV Placebo
- **BIOLOGICAL:** HAV Vaccine Placebo

## Key facts

- **NCT ID:** NCT03525119
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-16
- **Primary completion:** 2018-10-03
- **Final completion:** 2019-07-09
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525119, "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03525119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*